iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO ), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate.

Following a single dose of IBIO-610, active Activin E levels in the blood were reduced in all treated NHPs and remained suppressed through eight weeks.

At both weeks 4 and 8, active Activin E levels were reduced to levels below the limits of the assay.

Overall, active Activin E was reduced by 98% at week 4 and 97% at week 8 compared with baseline.

These findings support IBIO-610's potential for best-in-class pathway inhibition and further support the potential for an infrequently dosed, long-acting antibody approach.

The data also demonstrated IBIO-610's potential to promote fat-selective weight loss while preserving lean mass.

In obese NHPs, when combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone, further supporting its potential as both a stand-alone therapy and a complementary approach to GLP-1-based treatments.